In vivo Associate Scientist

Analytical Development Lab Manager

Quality Control Associate Analyst

Quality Control Lab Technician

Scientist

Scientist for Novel mRNA-based Gene Therapies

Non-oncology Scientist

Non-oncology Senior Scientist

Scientist or Senior Scientist, Cell/Gene Therapy

Principal Scientist, Cell/Gene Therapy

Scientist or Senior Scientist, In Vivo Gene Therapy

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

AllStripes

Alltrna

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

ALX Oncology

Alzheon

Ambagon Therapeutics

Amberstone Biosciences

Ambys Medicines

Amylyx

AN2 Therapeutics

Andes

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Ansa Biotechnologies

Antheia

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio (Flagship)

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Arbor Biotechnologies

Arcadia Science

Arcellx

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Aro Biotherapeutics

Arpeggio Biosciences

Arrakis Therapeutics

Arranta Bio

ArsenalBio

Artisan Bio

Artiva Biotherapeutics

Ascidian Therapeutics

Ascribe Bioscience

Asher Biotherapeutics

Asimov

Carisma Therapeutics is developing novel chimeric antigen receptor (CAR) macrophage technology to treat solid tumors. Engineering T cells with CARs has shown great advances in the treatment of hematologic malignancies, but such results have not been translated to solid tumors. Macrophages are a key component of the immune system that eat cancer cells from solid tumors. Carisma is engineering macrophages with CARs to redirect their activity towards tumor cells to provide long-term anti-tumor immunity. Carisma’s lead candidate, CT-0508, is an ex vivo gene-modified autologous therapy to treat HER2 solid tumors in Phase 1 development. Carisma is also working on allogeneic CAR-Macrophages that would provide an off-the-shelf product enabling more patients to benefit from their cell therapies.

<p>Claim company profile to add description</p>


Carisma Therapeutics

Find a biotech startup* job.